Literature DB >> 16182400

Liposomalization of SN-38 as active metabolite of CPT-11.

Yasuyuki Sadzuka1, Hiroyuki Takabe, Takashi Sonobe.   

Abstract

Although many drugs have been developed for the treatment of disease, some drugs have complications such as adverse effects, and antitumor agents should target tumors or cells more selectively. It is therefore necessary to develop drug delivery systems, and liposomes are reportedly useful as an effective drug carrier. An antitumor agent, CPT-11, inhibits DNA synthesis by the inhibition of topoisomerase1 and has a strong antitumor activity. SN-38 is converted from CPT-11 as an active metabolite by carboxylesterase in the liver. As SN-38 is insoluble, it has not been applied at the clinical stage as an injection. It is expected that SN-38 liposomalization may increase its usefulness in cancer chemotherapy. Our purpose is to have a clinical application of SN-38 by a novel method of liposomalization to expand the application for the other insolubility drugs. As SN-38 is hydrophobic, SN-38-trapped liposome preparation was attempted using the Bangham method, which is effective for general preparation. However, a high ratio of SN-38 trapped in liposome was not achieved, and this was not improved by the freezing-thawing method or the freeze-drying method. On the other hand, the ratio of SN-38 trapped in liposome by the modified remote loading method was about 4 times that by the Bangham method, and the ratio by the film loading method, novel method of liposomal preparation, reached 2 times and 8 times that by the modified remote loading method and Bangham method, respectively, showing a remarkable increase. In conclusion, it was suggested that the preparation of SN-38 liposome using the film loading method effectively entraps SN-38. Thus, it is expected that SN-38 liposome can be applied as an injection. This preparation method is useful if application is possible in the other insolubility drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16182400     DOI: 10.1016/j.jconrel.2005.08.023

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  9 in total

1.  The synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release.

Authors:  Baohua Huang; Ankur Desai; Shengzhuang Tang; Thommey P Thomas; James R Baker
Journal:  Org Lett       Date:  2010-04-02       Impact factor: 6.005

2.  Lipids including cholesteryl linoleate and cholesteryl arachidonate contribute to the inherent antibacterial activity of human nasal fluid.

Authors:  Thai Q Do; Safiehkhatoon Moshkani; Patricia Castillo; Suda Anunta; Adelina Pogosyan; Annie Cheung; Beth Marbois; Kym F Faull; William Ernst; Su Ming Chiang; Gary Fujii; Catherine F Clarke; Krishna Foster; Edith Porter
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

3.  Magnetic-Fe/Fe(3)O(4)-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for the delivery to tumors within monocytes/macrophages.

Authors:  Hongwang Wang; Tej B Shrestha; Matthew T Basel; Raj Kumar Dani; Gwi-Moon Seo; Sivasai Balivada; Marla M Pyle; Heidy Prock; Olga B Koper; Prem S Thapa; David Moore; Ping Li; Viktor Chikan; Deryl L Troyer; Stefan H Bossmann
Journal:  Beilstein J Nanotechnol       Date:  2012-06-13       Impact factor: 3.649

4.  Effect of liposomal celecoxib on proliferation of colon cancer cell and inhibition of DMBA-induced tumor in rat model.

Authors:  Venkatesan Perumal; Shubhadeep Banerjee; Shubasis Das; R K Sen; Mahitosh Mandal
Journal:  Cancer Nanotechnol       Date:  2011-07-13

5.  High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile.

Authors:  Rajesh Mukthavaram; Pengfei Jiang; Rohit Saklecha; Dmitri Simberg; Ila Sri Bharati; Natsuko Nomura; Ying Chao; Sandra Pastorino; Sandeep C Pingle; Valentina Fogal; Wolf Wrasidlo; Milan Makale; Santosh Kesari
Journal:  Int J Nanomedicine       Date:  2013-10-21

6.  In vitro and in vivo evaluation of SN-38 nanocrystals with different particle sizes.

Authors:  Min Chen; Wanqing Li; Xun Zhang; Ye Dong; Yabing Hua; Hui Zhang; Jing Gao; Liang Zhao; Ying Li; Aiping Zheng
Journal:  Int J Nanomedicine       Date:  2017-08-01

7.  One-step mechanochemical preparation and prominent antitumor activity of SN-38 self-micelle solid dispersion.

Authors:  Xuanrong Sun; Dabu Zhu; Yue Cai; Guobang Shi; Mengshi Gao; Minzi Zheng
Journal:  Int J Nanomedicine       Date:  2019-03-26

8.  Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study.

Authors:  Chan Wu; Yang Zhang; Daoqiu Yang; Jinfeng Zhang; Juanjuan Ma; Dan Cheng; Jianming Chen; Li Deng
Journal:  Int J Nanomedicine       Date:  2018-12-20

9.  A novel microfluidic liposomal formulation for the delivery of the SN-38 camptothecin: characterization and in vitro assessment of its cytotoxic effect on two tumor cell lines.

Authors:  Ana Casadó; M Lluïsa Sagristá; Margarita Mora
Journal:  Int J Nanomedicine       Date:  2018-09-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.